169.80
5.71 (3.48%)
| Penutupan Terdahulu | 164.09 |
| Buka | 163.07 |
| Jumlah Dagangan | 1,740,748 |
| Purata Dagangan (3B) | 882,229 |
| Modal Pasaran | 4,246,217,984 |
| Harga / Jualan (P/S) | 507.09 |
| Harga / Buku (P/B) | 13.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -2,868.84% |
| EPS Cair (TTM) | -10.66 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,349.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.24% |
| Nisbah Semasa (MRQ) | 8.44 |
| Aliran Tunai Operasi (OCF TTM) | -163.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -90.04 M |
| Pulangan Atas Aset (ROA TTM) | -39.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -63.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Praxis Precision Medicines, Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -1.00 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.16% |
| % Dimiliki oleh Institusi | 122.02% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 507.00 (BTIG, 198.59%) | Beli |
| Median | 322.50 (89.93%) | |
| Rendah | 83.00 (Wedbush, -51.12%) | Jual |
| 83.00 (Jones Trading, -51.12%) | Beli | |
| Purata | 294.80 (73.62%) | |
| Jumlah | 9 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 195.99 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 08 Dec 2025 | 507.00 (198.59%) | Beli | 247.99 |
| 19 Nov 2025 | 424.00 (149.71%) | Beli | 189.32 | |
| HC Wainwright & Co. | 08 Dec 2025 | 340.00 (100.24%) | Beli | 247.99 |
| 05 Dec 2025 | 340.00 (100.24%) | Beli | 247.99 | |
| Needham | 08 Dec 2025 | 315.00 (85.51%) | Beli | 247.99 |
| 05 Dec 2025 | 304.00 (79.03%) | Beli | 247.99 | |
| Wedbush | 05 Dec 2025 | 83.00 (-51.12%) | Jual | 247.99 |
| 06 Nov 2025 | 77.00 (-54.65%) | Jual | 172.35 | |
| Chardan Capital | 17 Oct 2025 | 330.00 (94.35%) | Beli | 189.99 |
| Deutsche Bank | 17 Oct 2025 | 280.00 (64.90%) | Beli | 189.99 |
| Guggenheim | 17 Oct 2025 | 350.00 (106.12%) | Beli | 189.99 |
| Truist Securities | 17 Oct 2025 | 360.00 (112.01%) | Beli | 189.99 |
| Jefferies | 16 Oct 2025 | 300.00 (76.68%) | Beli | 162.71 |
| Jones Trading | 18 Sep 2025 | 83.00 (-51.12%) | Beli | 45.23 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |